Management strengthens its commitment to a
successful upcoming market launch of RepliCel's dermal injector and
consumables product line by addition of Damien King
VANCOUVER, Aug. 29, 2019 /CNW/ - RepliCel Life Sciences
Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2) ("RepliCel" or the
"Company"), a company developing next-generation technologies in
aesthetics and orthopedics, announces it has retained the services
of Damien King, an aesthetic
dermatology product specialist and former executive in several
top-tier companies, to help build out the global commercial
strategy for the Company's automated dermal injector, RCI-02, and
related consumables (the "RCI-02 Product Line"). RepliCel's
RCI-02 Product Line is expected to market launch next year in
Europe and Hong Kong after receiving CE marketing
approval in the first half of 2020.
Mr. King has more than 20 years of in-depth experience in the
sales and marketing of pharmaceutical, biologic, and medical device
products for some of the world's largest life science companies.
Most recently he was a Director of Sales and Franchise Development
for Merz Pharmaceuticals with past experience including roles with
Allergan, Purdue and Eli Lilly. Mr.
King holds a Bachelor of Science and a Master of Business
Administration from Cornell University.
He currently sits on the Board of Directors for Aequus
Pharmaceuticals and has recently launched Avari Medical to
distribute emerging and innovative products in the aesthetic and
dermatology sector to select markets.
"Bringing Damien King on board
along with his extensive consulting network of leading dermatology
experts in clinical affairs, regulatory compliance, sales and
marketing, and business analysis," stated RepliCel President &
CEO, R. Lee Buckler, "is a perfect
complement to our existing team of experts including our Chief
Medical Officer and practicing medical dermatologist, Dr.
Rolf Hoffmann, our Head of Clinical
and Regulatory Affairs, Dr. Petra
Goessens-Rueck, and our medical device engineering partner,
the Agency for Medical Innovations."
"With the anticipated marketing approval of the products in
RepliCel's RCI-02 Product Line in the first half of next year,
RepliCel management is currently heavily engaged in developing its
global commercial strategy. Mr. King and team have been retained to
provide critical insights and advice on all aspects of the business
modelling and its execution including the targeted clinical
applications, pricing, marketing, key opinion leader engagement,
and sales and distribution," Buckler summarized.
About the RCI-02 Product Line
RepliCel's RCI-02 injector was designed with input from
dermatologists, industrial designers, and electronic and medical
device engineers to improve the delivery of a variety of
injectables in a controlled, precise manner, removing the risks and
uncertainties of injection outcomes currently resulting from
manually operated, single-needle syringes.
The RCI-02 Product Line is now in the final stages of
development with final prototypes expected within the next few
weeks after which the Company will transition to product
manufacture, testing, and regulatory marketing approval. Upon
successful delivery and assessment of the final device prototypes,
a first production run of commercial-grade units of the RCI-02
injector and related consumables will be manufactured later this
year to be used for both functional testing and clinical safety
evaluation.
RCI-02 dermal injector is the world's first motorized injection
device with programmable depth and volume, a built-in Peltier
element for pre-injection numbing of the skin and interchangeable
needle head configurations. It is designed to deliver a variety of
injectable substances, including cells, dermal fillers, drugs or
biologics intradermally (dermis) and subcutaneously (fat) via an
array of needle configurations, starting with a 16-needle
configuration (4×4) on one head. This needle head will be
used to perform a variety of procedures, increase surface area
coverage and speed-up procedure times.
RCI-02 automates and simplifies the injection
process. Equipped with a touch screen on its accompanying
docking station, the device's programmability allows for the
delivery of precise quantities of material, at specific depths,
through fine-gauge needles, on a single plain or trailing through
multi-plains, as the needle retracts through the skin.
Overall benefits of this next-generation dermal injector
technology are anticipated to include improved handling, reduction
or elimination of the need for pre-injection local anesthetic,
quicker procedure times, improved patient experience, and a
significant expansion of the areas that can be addressed with
dermal fillers due to the ability to conduct broad, shallow and
evenly-dispersed injections.
The Company anticipates marketing approval to launch sales of
the initial RCI-02 Product Line next year. Management is
committed to being fully prepared for market launch in Europe and Hong
Kong in 2020 as it continues to plan for further product
line innovation and pursue marketing approvals in the United States, Asia, and other key global markets.
About RepliCel Life Sciences
RepliCel is a
regenerative medicine company focused on developing cell therapies
for aesthetic and orthopedic conditions affecting what the Company
believes is approximately one in three people in industrialized
nations, including aging/sun-damaged skin, pattern baldness, and
chronic tendon degeneration. These conditions, often
associated with aging, are caused by a deficit of healthy cells
required for normal tissue healing and function. The Company's
product pipeline is comprised of RCT-01 for tendon repair, RCS-01
for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is
currently being co-developed with, and under exclusive license by,
Shiseido for certain Asian countries. All product candidates are
based on RepliCel's innovative technology, utilizing cell
populations isolated from a patient's healthy hair follicles.
RepliCel has also developed a proprietary injection device, RCI-02,
optimized for the administration of its products and licensable for
use with other dermatology applications. Please
visit www.replicel.com for additional information.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/replicel-life-sciences-retains-dermatology-sales-and-marketing-executive-to-guide-the-global-commercial-strategy-for-its-automated-dermal-injector-300908770.html
SOURCE RepliCel Life Sciences Inc.